TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.17.

A number of research analysts recently issued reports on TGTX shares. StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 24th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of TG Therapeutics in a report on Wednesday, February 28th. Finally, B. Riley lifted their target price on TG Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, February 5th.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Cim Investment Management Inc. lifted its stake in shares of TG Therapeutics by 3.6% in the first quarter. Cim Investment Management Inc. now owns 15,521 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 535 shares in the last quarter. New York State Common Retirement Fund increased its holdings in TG Therapeutics by 1.2% during the 4th quarter. New York State Common Retirement Fund now owns 56,208 shares of the biopharmaceutical company’s stock worth $960,000 after purchasing an additional 663 shares in the last quarter. Kestra Advisory Services LLC raised its stake in shares of TG Therapeutics by 8.2% in the third quarter. Kestra Advisory Services LLC now owns 16,342 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 1,240 shares during the last quarter. Arizona State Retirement System lifted its holdings in shares of TG Therapeutics by 3.5% in the third quarter. Arizona State Retirement System now owns 40,411 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 1,356 shares in the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in shares of TG Therapeutics by 2.5% during the third quarter. Valeo Financial Advisors LLC now owns 61,800 shares of the biopharmaceutical company’s stock valued at $517,000 after buying an additional 1,500 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $14.16 on Friday. The company’s 50 day moving average price is $15.21 and its two-hundred day moving average price is $13.76. The firm has a market capitalization of $2.19 billion, a P/E ratio of 708.35 and a beta of 2.30. TG Therapeutics has a fifty-two week low of $6.46 and a fifty-two week high of $35.67. The company has a debt-to-equity ratio of 0.62, a current ratio of 5.92 and a quick ratio of 5.18.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The company had revenue of $43.97 million for the quarter, compared to the consensus estimate of $40.06 million. During the same quarter last year, the business posted ($0.39) EPS. On average, equities analysts forecast that TG Therapeutics will post -0.12 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.